Post-Transplant Cyclophosphamide
Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 56 patients (estimated)
- Sponsors
- National Heart, Lung, and Blood Institute (NHLBI)
- Tags
- Allogeneic Stem Cell Transplant, Chemotherapy
- Trial Type
- Treatment
- Last Update
- 2 days ago
- SparkCures ID
- 1584
- NCT Identifier
- NCT03520647
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.